Skip to main content

Advertisement

SpringerLink
Log in

Chronic oral etoposide in advanced breast cancer

  • Short Communication
  • Etoposide, Chronic Oral Etoposide, Chemotherapy, Breast Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Chronic oral etoposide has shown activity in some metastatic refractory tumors. To test its activity in previously treated metastatic breast cancer patients, we started a study in 18 consecutive patients given etoposide orally at 50 mg/m2 daily for 21 days. A partial response was observed in 4 of 18 patients (22%); of the responding patients, 3 had visceral metastases and 1 had multiple bone metastases. Leukopenia of grade 3 or 4 was the main hematological toxic effect (23% of patients) and alopecia was the most important nonhematological toxicity. Chronic oral etoposide shows some activity in pretreated patients with metastatic breast cancer, with tolerance being good and toxicity, acceptable. Further studies of this drug given as first-line chemotherapy or in combination with other drugs can establish all its potential activity in this cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ahmann DL, Bisel HF, Eagan RT, et al (1976) Phase II evaluation of VP16-213 (NSC-141540) and Cytembena (NSC-104801) in patients with advanced breast cancer. Cancer Treat Rep 60: 633–635

    Google Scholar 

  2. Cavalli F, Sonntag RW, Jungi F, et al (1978) VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 62:473

    Google Scholar 

  3. Glark GM, Sledge GW Jr, Osborne CK, McGuire WL (1987) Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5:55

    Google Scholar 

  4. Haskell CM, et al (1985) Breast cancer. In: Haskell CM (ed) Cancer treatment. W. B. Saunders, Philadelphia, pp 137–180

    Google Scholar 

  5. Henderson IC, Harris JR, Kinne DW, Hellman S (1989) Cancer of the breast. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds) Cancer, principles and practice of oncology. J. B. Lippincott, Philadelphia, p 1197

    Google Scholar 

  6. Dombernbwsky P, Nissen NI (1973) Schedule dependency of the antileukemic activity of the podophyllotoxin derivative VP16-213 (NSC-141540) in 11210 leukemia. Acta Pathol Microbiol Scand [A] 81:715

    Google Scholar 

  7. Estapé J, Palombo H, Sanchez-Lloret J, et al (1992) Chronic oral etoposide in non-small cell lung carcinoma. Eur J Cancer 28A:835

    Google Scholar 

  8. Fraschini G, Esparza L, Holmes F, et al (1989) High-dose etoposide (HD-E) in metastatic breast cancer (abstract). Breast Cancer Res Treat 14:142

    Google Scholar 

  9. Greco FA, Johnson DH, Hainsworth JD, et al (1989) Chronic oral etoposide. Cancer 67 [Suppl]:303

    Google Scholar 

  10. Hainsworth JD, Greco A, Johnson D, et al (1990) Chronic daily administration of oral etoposide: a phase I trial. J Clin Oncol 3:395

    Google Scholar 

  11. Johnson DH, Greco FA, Strupp J, et al (1990) Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 8:1613

    Google Scholar 

  12. Liu LF, Rowe TG, Yang L, et al (1984) Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 259:13560

    Google Scholar 

  13. Miller JC, Loehrer FJ, Williams SD, et al (1989) Phase II study of daily oral VP-16 in refractory germ cell tumours (abstract). Proc Am Soc Clin Oncol 8:145

    Google Scholar 

  14. Ross W, Rowe T, Glisson B, Yalowich J, Liu L (1984) Role of topoisomerase II in mediating epipodophyllotoxin induced DNA cleavage. Cancer Res 44:5857

    Google Scholar 

  15. Schell FC, Yap HY, Hortobagyi GN, et al (1982) Phase II study of VP-16-213 (etoposide) in refractory metastatic breast carcinoma. Cancer Chemother Pharmacol 7:223

    Google Scholar 

  16. Sledge GW Jr (1991) Etoposide in the management of metastatic breast cancer. Cancer 67 [Suppl]:266

    Google Scholar 

  17. Slevin ML, Clark PI, Osborne RJ, et al (1986) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. Proc Am Soc Clin Oncol 5:175

    Google Scholar 

  18. Sullivan DM, Glisson BS, Hodges PK, et al (1986) Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 25:2248

    Google Scholar 

  19. Vaughn CB, Panettiere F, Thigpen T, et al. (1981) Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group study. Cancer Treat Rep 65:443

    Google Scholar 

  20. World Health Organization (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva

    Google Scholar 

  21. Miller AB, Hoogstraten B, Staquet M, et al (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Google Scholar 

  22. Gehan EA (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:4

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic Hospital, Medical Oncology Department, University of Barcelona, 170 Villarroel, E-08036, Barcelona, Spain

    H. Palombo, J. Estapé, N. Viñolas, J. J. Grau, J. M. Mañé, M. Daniels & B. Mellado

Authors
  1. H. Palombo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Estapé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Viñolas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. J. Grau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. M. Mañé
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Daniels
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Mellado
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palombo, H., Estapé, J., Viñolas, N. et al. Chronic oral etoposide in advanced breast cancer. Cancer Chemother. Pharmacol. 33, 527–529 (1994). https://doi.org/10.1007/BF00686513

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686513

Keywords

Search

Navigation